18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

24 August 2020 - Event

4th AMR Conference Novel Antimicrobial & AMR Diagnostics – Delivered Digitally

In view of the continuing uncertain situation and travel restrictions due to the COVID-19 pandemic, we have decided to implement…

09 July 2020 - Event

Global Launch – Virtual Event from Berlin: NEW INITIATIVE TAKES ON THE ANTIBIOTIC INNOVATION CHALLENGE

The world is losing its most powerful tool in healthcare: antibiotics. We need to take action now. Organized by IFPMA,…

10 July 2020 - BEAM Alliance

BEAM Alliance – Reflexion paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

BEAM News
Member News
Events

Latest news of BEAM Alliance

10 July 2020 - BEAM Alliance

BEAM Alliance – Reflexion paper on the EU Pharmaceutical Strategy Roadmap

BEAM welcome the European Commission's ambition to support innovation in its upcoming Pharmaceutical Strategy. In our latest paper , we…

02 April 2020 - BEAM Alliance

Request for Proposals (RFP) for an Agreement for Performance of Work (APW) to develop an online e-learning course on antimicrobial stewardship

To support the Antimicrobial Stewardship and Awareness (ASA) Unit in the Global Coordination and Partnership on Antimicrobial Resistance (GCP) department…

03 December 2019 - BEAM Alliance

New IMI project “COMBINE” launched to accelerate the fight against antimicrobial resistance

The aim of the IMI Antimicrobial Resistance (AMR) Accelerator is to progress the development of new medicines to treat or…

18 November 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PULL Incentives: ‘Incentivising a sustainable response to the threat of AMR’

Without adequate incentives it is anticipated that in less than 2 years from now, many AMR SMEs will have disappeared…

18 November 2019 - BEAM Alliance

New BEAM Alliance Position Paper calls out stakeholders to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance

The European BEAM Alliance, representing 72 ‘Biotech companies from Europe innovating in AntiMicrobial resistance research’, today released a position paper…

19 July 2019 - BEAM Alliance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

The BEAM Alliance proposed a six-way approach to characterize ATM activity, with the aim of opening new doors in the…

page 1/3

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

28 July 2020 - Polyphor Ltd

Polyphor strengthens financial flexibility with CHF 19.3 million equity-linked financing

We are encouraged by the progress we have made in implementing Polyphor’s renewed strategy to advance our pipeline in oncology…

23 July 2020 - Nabriva Therapeutics GmbH

Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study

XENLETA® (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for administration in humans discovered and developed by the Nabriva Therapeutics team.…

16 July 2020 - Nabriva Therapeutics GmbH

XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia

XENLETA is a pleuromutilin antibacterial indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following…

15 July 2020 - DEINOVE

DEINOVE: DNV3837 antibiotic candidate: the Phase II trial continues in the United States, despite a disrupted context due to the COVID-19 outbreak

« We are grateful to the clinicians for doing their utmost to ensure that the clinical trial runs smoothly. We…

14 July 2020 - BioVersys AG

BioVersys and Partners from Lille Sign Long-term Collaboration Agreement Creating a Unique Cross-Border AMR Cluster in Antimicrobial Research Excellence

BioVersys and partners, the Institut Pasteur de Lille and the University of Lille, from Région Hauts-de-France, sign a long-term collaboration…

07 July 2020 - VAXDYN

Vaxdyn’s new vaccine against Gram-negative pathogens, if approved, would help curb the rising threat of drug resistant bacteria

New drugs urgently needed to address the global superbug crisis

page 1/21

Events

25 June 2020

REVIVE Webinar: Putting children first in the fight against antibiotic resistance

Speakers: - Dr Christina Obiero, co-investigator for GARDP fosfomycin clinical trial in Kilifi, Kenya - Dr Manica Balasegaram, Executive Director,…

25 June 2020

JPIAMR webinar series on antibiotic use and the risk for increased antibiotic resistance in the COVID-19 pandemic

The burden of AMR is likely to increase due to the escalated use of antibiotics to treat bacterial co-infections in…

25 June 2020

tranScrip: COVID-19 Panel Discussion: Successful Medical Affairs in the “New Normal” after COVID-19

During this hour-long panel discussion, we will hear from those embracing virtual medical affairs in a world with COVID-19.

25 June 2020

tranScrip is delighted to announce that one of the trials they have been involved in running on COVID 19 has generated positive results

tranScrip is a specialist drug development and lifecycle management service provider based in the UK with small satellite offices in…

16 June 2020

REVIVE Webinar: Bringing new treatments for drug-resistant infections to all who need them

The following topics will be presented: - Antibiotic resistance and the GARDP response - Tackling the growing threat of hospital…

09 June 2020

REVIVE Webinar: Test tube to patient: PK/PD of fixed dose beta-lactam/beta-lactamase inhibitor combinations

Topics discussed will include: - Understanding the inherent challenges associated with PK/PD of BL/BLI combinations - Demonstrating new approaches to…

04 June 2020

Antimicrobial Resistance: The Requirement for a New Business Model for the Development, Production and Sales of New Antibiotics

The online event will look at the requirement for a new business model for the development, production and sales of…

19 May 2020

REVIVE Webinar: Assay development for measuring antibiotic accumulation in Gram-negative bacteria

Assay development for measuring antibiotic accumulation in Gram-negative bacteria

12 May 2020

REVIVE Webinar: Probability of target attainment analyses for dose selection in antimicrobial drug development

Topics discussed will include: - An overview of what is meant by the probability of target attainment (PTA) - How…

page 2/7